Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data

Abstract Background Since the results of the ToGA trial were published, trastuzumab-based chemotherapy has been used as the standard first-line treatment for HER2-positive recurrent or primary metastatic gastric cancer (RPMGC). However, the real-world data has been rarely reported. Therefore, we investigated the outcomes of trastuzumab-based chemotherapy in a single center. Methods This study analyzed the real-world data of 47 patients with HER2-positive RPMGC treated with trastuzumab-based chemotherapy in a single institution. Results With the median follow-up duration of 18.8 months in survivors, the median overall survival (OS) and progression-free survival were 12.8 and 6.9 months, respectively, and the overall response rate was 64%. Eastern Cooperative Oncology Group performance status 2 and massive amount of ascites were independent poor prognostic factors for OS, while surgical resection before or after chemotherapy was associated with favorable OS, in multivariate analysis. In addition, 5 patients who underwent conversion surgery after chemotherapy demonstrated an encouraging median OS of 30.8 months, all with R0 resection. Conclusions Trastuzumab-based chemotherapy in patients with HER2-positive RPMGC in the real world demonstrated outcomes almost comparable to those of the ToGA trial. Moreover, conversion surgery can be actively considered in fit patients with a favorable response after trastuzumab-based chemotherapy.

Download Full-text

Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2018.03.019 ◽

2018 ◽

Vol 44 (8) ◽

pp. 1191-1198 ◽

Cited By ~ 16

Author(s):

Alberto Carmona-Bayonas ◽

Paula Jiménez-Fonseca ◽

Isabel Echavarria ◽

Manuel Sánchez Cánovas ◽

Gema Aguado ◽

...

Keyword(s):

Gastric Cancer ◽

Real World ◽

National Registry ◽

Real World Data ◽

World Data ◽

The Real

Download Full-text

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

Cancers ◽

10.3390/cancers11010010 ◽

2018 ◽

Vol 11 (1) ◽

pp. 10 ◽

Cited By ~ 13

Author(s):

Michael Lux ◽

Naiba Nabieva ◽

Andreas Hartkopf ◽

Jens Huober ◽

Bernhard Volz ◽

...

Keyword(s):

Breast Cancer ◽

Real World ◽

Eastern Cooperative Oncology Group ◽

Metastatic Breast ◽

Her2 Positive ◽

Real World Data ◽

World Data ◽

Cancer Data ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH, 85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH → T-DM1 was administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative hormone receptor status, and visceral or brain metastases were associated with more frequent use of this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients. As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of this sequence is similar to that in the approval study.

Download Full-text